vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and Phunware, Inc. (PHUN). Click either name above to swap in a different company.
Phunware, Inc. is the larger business by last-quarter revenue ($1.0M vs $906.0K, roughly 1.1× Mind Medicine (MindMed) Inc.). Phunware, Inc. runs the higher net margin — -260.2% vs -2634.0%, a 2373.8% gap on every dollar of revenue. On growth, Mind Medicine (MindMed) Inc. posted the faster year-over-year revenue change (-16.1% vs -21.9%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Phunware Inc. is a publicly traded enterprise software company headquartered in Austin, Texas. Founded in 2009, Phunware builds cloud-based platforms that help brands and governments engage users across mobile and digital environments. Its core products include solutions for mobile app development, location-based services, digital advertising, and data-driven engagement.
DFTX vs PHUN — Head-to-Head
Income Statement — Q4 FY2023 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $1.0M |
| Net Profit | $-23.9M | $-2.6M |
| Gross Margin | — | 46.5% |
| Operating Margin | -2450.8% | -290.2% |
| Net Margin | -2634.0% | -260.2% |
| Revenue YoY | -16.1% | -21.9% |
| Net Profit YoY | -386.7% | 59.7% |
| EPS (diluted) | $-0.58 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | $921.0K | ||
| Q4 23 | $906.0K | $941.0K | ||
| Q3 23 | $1.2M | $1.3M | ||
| Q2 23 | $1.3M | $1.3M | ||
| Q1 23 | $1.3M | $1.3M | ||
| Q4 22 | $1.1M | $-10.5M | ||
| Q3 22 | $360.0K | $4.8M |
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-2.3M | ||
| Q4 23 | $-23.9M | $-23.0M | ||
| Q3 23 | $-17.9M | $-19.0M | ||
| Q2 23 | $-29.1M | $-6.5M | ||
| Q1 23 | $-24.8M | $-4.3M | ||
| Q4 22 | $-4.9M | $-10.9M | ||
| Q3 22 | $-16.5M | $-8.0M |
| Q2 24 | — | 46.5% | ||
| Q1 24 | — | 56.9% | ||
| Q4 23 | — | 47.5% | ||
| Q3 23 | — | 50.4% | ||
| Q2 23 | — | 41.3% | ||
| Q1 23 | — | 5.4% | ||
| Q4 22 | — | — | ||
| Q3 22 | — | 16.7% |
| Q2 24 | — | -290.2% | ||
| Q1 24 | — | -312.1% | ||
| Q4 23 | -2450.8% | -2086.3% | ||
| Q3 23 | -1858.6% | -1060.5% | ||
| Q2 23 | -2226.1% | -470.0% | ||
| Q1 23 | -1624.8% | -498.1% | ||
| Q4 22 | -1287.0% | — | ||
| Q3 22 | -4717.5% | -165.6% |
| Q2 24 | — | -260.2% | ||
| Q1 24 | — | -248.9% | ||
| Q4 23 | -2634.0% | -2445.6% | ||
| Q3 23 | -1541.1% | -1515.9% | ||
| Q2 23 | -2222.0% | -503.8% | ||
| Q1 23 | -1932.6% | -317.6% | ||
| Q4 22 | -454.0% | 103.7% | ||
| Q3 22 | -4579.2% | -168.5% |
| Q2 24 | — | $-0.32 | ||
| Q1 24 | — | $-0.33 | ||
| Q4 23 | $-0.58 | — | ||
| Q3 23 | $-0.45 | $-0.16 | ||
| Q2 23 | $-0.76 | $-0.06 | ||
| Q1 23 | $-0.65 | $-0.04 | ||
| Q4 22 | $-0.02 | $-0.11 | ||
| Q3 22 | $-0.56 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | $14.1M |
| Total Assets | $124.5M | $23.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | — | $20.4M | ||
| Q1 24 | — | $21.6M | ||
| Q4 23 | $99.7M | $3.9M | ||
| Q3 23 | $117.7M | $2.9M | ||
| Q2 23 | $116.9M | $1.1M | ||
| Q1 23 | $129.4M | $694.0K | ||
| Q4 22 | $142.1M | $2.0M | ||
| Q3 22 | $154.5M | $8.5M |
| Q2 24 | — | $14.1M | ||
| Q1 24 | — | $14.6M | ||
| Q4 23 | $78.1M | $-11.5M | ||
| Q3 23 | $96.0M | $6.6M | ||
| Q2 23 | $106.0M | $17.9M | ||
| Q1 23 | $130.3M | $21.9M | ||
| Q4 22 | $150.9M | $24.9M | ||
| Q3 22 | $153.6M | $32.8M |
| Q2 24 | — | $23.1M | ||
| Q1 24 | — | $24.3M | ||
| Q4 23 | $124.5M | $6.7M | ||
| Q3 23 | $141.6M | $27.8M | ||
| Q2 23 | $142.1M | $40.8M | ||
| Q1 23 | $155.5M | $45.5M | ||
| Q4 22 | $170.0M | $54.8M | ||
| Q3 22 | $180.9M | $68.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $-2.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | — | $-2.7M | ||
| Q1 24 | — | $-5.5M | ||
| Q4 23 | $-20.6M | $-2.6M | ||
| Q3 23 | $-16.6M | $-3.3M | ||
| Q2 23 | $-13.8M | $-5.2M | ||
| Q1 23 | $-13.3M | $-7.4M | ||
| Q4 22 | $-12.8M | $-4.0M | ||
| Q3 22 | $-9.3M | $-7.9M |
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 0.0% | ||
| Q3 23 | — | 0.0% | ||
| Q2 23 | — | 0.0% | ||
| Q1 23 | — | 0.0% | ||
| Q4 22 | — | 0.0% | ||
| Q3 22 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
